Investor Overview

Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company was founded to help stop the current coronavirus pandemic (COVID-19) and prevent the next. Pardes scientists developed a novel oral antiviral treatment for COVID-19, pomotrelvir, from concept through phase 2 testing in under three years. In addition, our research efforts have generated highly potent new chemical entities with broad spectrum pan-coronavirus activity to help better prepare for future threats. Our lead program, pomotrelvir, our research assets, and intellectual property are available for partnering while the company explores a range of strategic alternatives. Contact us here.

Stock
Quote

Webcasts

02/14/2023
at 1:40 PM EST
11/15/2022
at 12:00 AM PST
06/09/2022
at 11:30 AM EDT

Financial Information

Document Date Description Form View

Filing of certain prospectuses and communications in connection with business combination transactions

425 View HTML

Form of prospectus disclosing information facts events covered in both forms 424B1 424B3

424B4 View HTML

Form of prospectus reflecting facts events constituting substantive change from last form

424B3 View HTML

Form of prospectus reflecting facts events constituting substantive change from last form

424B3 View HTML

Form of prospectus reflecting facts events constituting substantive change from last form

424B3 View HTML

Form of prospectus reflecting facts events constituting substantive change from last form

424B3 View HTML

Form of prospectus reflecting facts events constituting substantive change from last form

424B3 View HTML

Form of prospectus reflecting facts events constituting substantive change from last form

424B3 View HTML

Form of prospectus reflecting facts events constituting substantive change from last form

424B3 View HTML

Form of prospectus reflecting facts events constituting substantive change from last form

424B3 View HTML

Contact
IR

Send us an investor-related question using the form below.